Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
130

Summary

Conditions
  • Chronic Lymphocytic Leukemia
  • Non Hodgkin's Lymphoma
  • Small Lymphocytic Lymphoma
Type
Interventional
Phase
Phase 1
Design
Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphoma patients. This is to be...

This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase at the MTD or recommended oral dose.

Tracking Information

NCT #
NCT03893682
Collaborators
Not Provided
Investigators
Study Director: Rafael Bejar, MD, PhD Aptose Biosciences Inc.